AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pasithea Therapeutics Corp. Director's Dealing 2022

Aug 19, 2022

35389_dirs_2022-08-18_baf0eaf4-92f0-46cc-87d9-7d68bb54a009.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-08-17

Reporting Person: Shahinian Eric (Member of 10% owner group)
Reporting Person: Camac Capital, LLC (Member of 10% owner group.)
Reporting Person: Camac Fund, LP (Member of 10% owner group.)
Reporting Person: Camac Partners, LLC (Member of 10% owner group.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-17	Common Stock	P	155773	$1.2087	Acquired	1611329	Indirect

Footnotes

F1: The shares are held by Camac Fund, LP. ("Camac Fund"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC.